101. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan
- Author
-
Chia Ming Chang, B. Nagari, Angel Cooper, Vishwanath Pai, Nathalie Dartois, Sylvie Jouve, Sacchidanand Sarvajnamurthy Aradhya, and Yin Ching Chuang
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Efficacy ,Vomiting ,Nausea ,Taiwan ,India ,Minocycline ,Microbial Sensitivity Tests ,Tigecycline ,Aztreonam ,chemistry.chemical_compound ,Pharmacotherapy ,Double-Blind Method ,Vancomycin ,Internal medicine ,Immunology and Microbiology(all) ,medicine ,Complicated skin and skin structure infections ,Humans ,Immunology and Allergy ,Aged ,General Immunology and Microbiology ,business.industry ,Skin Diseases, Bacterial ,General Medicine ,Middle Aged ,Anti-Bacterial Agents ,Surgery ,Clinical trial ,Infectious Diseases ,Tolerability ,chemistry ,Drug Therapy, Combination ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Background To compare the monotherapy of tigecycline with vancomycin-aztreonam in hospitalized patients from India and Taiwan with complicated skin and skin structure infections (cSSSIs). Methods Safety and efficacy data were analyzed for Indian ( n = 86) and Taiwanese ( n = 41) patients hospitalized with cSSSIs who participated in two international Phase 3, randomized, double-blind studies. Results Patients were treated for 5–14 days. Cure rates at the test-of-cure assessment (12–92 days post-therapy) were generally similar between tigecycline and vancomycin-aztreonam in the clinically evaluable populations (India, 83.3% vs. 75.8%; Taiwan, 78.6% vs . 90%) and in the clinical modified intent-to-treat populations (India, 78.6% vs. 66.7%; Taiwan, 73.3% vs . 75.0%). Nausea and vomiting occurred more frequently with tigecycline, but overall safety and tolerability were comparable between the two treatments. Conclusions Tigecycline monotherapy is a safe and effective therapy for cSSSIs in geographically distinct populations in Asia.
- Published
- 2011
- Full Text
- View/download PDF